全文获取类型
收费全文 | 3741篇 |
免费 | 288篇 |
国内免费 | 4篇 |
专业分类
电工技术 | 65篇 |
综合类 | 1篇 |
化学工业 | 1121篇 |
金属工艺 | 91篇 |
机械仪表 | 82篇 |
建筑科学 | 104篇 |
矿业工程 | 10篇 |
能源动力 | 118篇 |
轻工业 | 629篇 |
水利工程 | 33篇 |
石油天然气 | 14篇 |
无线电 | 258篇 |
一般工业技术 | 574篇 |
冶金工业 | 475篇 |
原子能技术 | 22篇 |
自动化技术 | 436篇 |
出版年
2024年 | 7篇 |
2023年 | 41篇 |
2022年 | 124篇 |
2021年 | 245篇 |
2020年 | 130篇 |
2019年 | 131篇 |
2018年 | 168篇 |
2017年 | 158篇 |
2016年 | 176篇 |
2015年 | 127篇 |
2014年 | 143篇 |
2013年 | 278篇 |
2012年 | 211篇 |
2011年 | 237篇 |
2010年 | 188篇 |
2009年 | 191篇 |
2008年 | 176篇 |
2007年 | 128篇 |
2006年 | 109篇 |
2005年 | 84篇 |
2004年 | 68篇 |
2003年 | 77篇 |
2002年 | 58篇 |
2001年 | 47篇 |
2000年 | 44篇 |
1999年 | 41篇 |
1998年 | 130篇 |
1997年 | 121篇 |
1996年 | 70篇 |
1995年 | 43篇 |
1994年 | 37篇 |
1993年 | 38篇 |
1992年 | 13篇 |
1991年 | 19篇 |
1990年 | 13篇 |
1989年 | 20篇 |
1988年 | 8篇 |
1987年 | 11篇 |
1986年 | 12篇 |
1985年 | 13篇 |
1984年 | 12篇 |
1983年 | 16篇 |
1982年 | 7篇 |
1981年 | 6篇 |
1980年 | 11篇 |
1979年 | 5篇 |
1978年 | 7篇 |
1977年 | 11篇 |
1976年 | 16篇 |
1973年 | 3篇 |
排序方式: 共有4033条查询结果,搜索用时 31 毫秒
1.
2.
Isabel Fernandes Cecília Melo-Alvim Raquel Lopes-Brs Miguel Esperana-Martins Luís Costa 《International journal of molecular sciences》2021,22(2)
Osteosarcoma (OS) is a rare condition with very poor prognosis in a metastatic setting. Basic research has enabled a better understanding of OS pathogenesis and the discovery of new potential therapeutic targets. Phase I and II clinical trials are already ongoing, with some promising results for these patients. This article reviews OS pathogenesis and new potential therapeutic targets. 相似文献
3.
4.
Gomes A. C. S. A. Costa L. C. Brito D. C. Frana R. J. Marques Mnica R. C. 《Polymer Bulletin》2020,77(4):1969-1981
Polymer Bulletin - In this study, we synthesized a new ion-imprinted polymer (IIP) based on introduction of amidoxime groups in acrylonitrile, complexation with Cd2+ ions and polymerization with... 相似文献
5.
6.
Adele Boccuto Filippo Dragoni Francesca Picarazzi Alessia Lai Carla Della Ventura Carla Veo Federica Giammarino Francesco Saladini Gianguglielmo Zehender Maurizio Zazzi Mattia Mori Ilaria Vicenti 《International journal of molecular sciences》2021,22(5)
The nucleotide analog sofosbuvir, licensed for the treatment of hepatitis C, recently revealed activity against the Zika virus (ZIKV) in vitro and in animal models. However, the ZIKV genetic barrier to sofosbuvir has not yet been characterized. In this study, in vitro selection experiments were performed in infected human hepatoma cell lines. Increasing drug pressure significantly delayed viral breakthrough (p = 0.029). A double mutant in the NS5 gene (V360L/V607I) emerged in 3 independent experiments at 40–80 µM sofosbuvir resulting in a 3.9 ± 0.9-fold half- maximal inhibitory concentration (IC50) shift with respect to the wild type (WT) virus. A triple mutant (C269Y/V360L/V607I), detected in one experiment at 80 µM, conferred a 6.8-fold IC50 shift with respect to the WT. Molecular dynamics simulations confirmed that the double mutant V360L/V607I impacts the binding mode of sofosbuvir, supporting its role in sofosbuvir resistance. Due to the distance from the catalytic site and to the lack of reliable structural data, the contribution of C269Y was not investigated in silico. By a combination of sequence analysis, phenotypic susceptibility testing, and molecular modeling, we characterized a double ZIKV NS5 mutant with decreased sofosbuvir susceptibility. These data add important information to the profile of sofosbuvir as a possible lead for anti-ZIKV drug development. 相似文献
7.
8.
9.
10.
Dr. Hui Qiu Richard Caldwell Dr. Lesley Liu-Bujalski Dr. Andreas Goutopoulos Reinaldo Jones Justin Potnick Dr. Brian Sherer Dr. Andrew Bender Dr. Roland Grenningloh Dr. Daigen Xu Dr. Anna Gardberg Dr. Igor Mochalkin Dr. Theresa Johnson Dr. Ariele Viacava Follis Jared Head Dr. Federica Morandi 《ChemMedChem》2019,14(2):217-223
Bruton's tyrosine kinase (Btk) is an attractive target for the treatment of a wide array of B-cell malignancies and autoimmune diseases. Small-molecule covalent irreversible Btk inhibitors targeting Cys481 have been developed for the treatment of such diseases. In clinical trials, probe molecules are required in occupancy studies to measure the level of engagement of the protein by these covalent irreversible inhibitors. The result of this pharmacodynamic (PD) activity provides guidance for appropriate dosage selection to optimize inhibition of the drug target and correlation of target inhibition with disease treatment efficacy. This information is crucial for successful evaluation of drug candidates in clinical trials. Based on the pyridine carboxamide scaffold of a novel solvent-accessible pocket (SAP) series of covalent irreversible Btk inhibitors, we successfully developed a potent and selective affinity-based biotinylated probe 12 (2-[(4-{4-[5-(1-{5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamido}-3,6,9,12-tetraoxapentadecan-15-amido)pentanoyl]piperazine-1-carbonyl}phenyl)amino]-6-[1-(prop-2-enoyl)piperidin-4-yl]pyridine-3-carboxamide). Compound 12 has been used in Btk occupancy assays for preclinical studies to determine the therapeutic efficacy of Btk inhibition in two mouse lupus models driven by TLR7 activation and type I interferon. 相似文献